12:00 AM
Feb 27, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AAV2-hRPE65v2: Additional Phase I data

Researchers at the university and colleagues reported data from 3 patients who received AAV2-hRPE65v2 in 1 eye in an open-label Phase I trial showing that a second treatment with AAV2-hRPE65v2 in the contralateral eye given 1.7-3.3 years after their initial treatment was safe with no adverse events...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >